Physician profile
Jonathan Blackmon
NPI 1679142335
$633.58
in general payments reported to CMS, 2019-2025
13 companies · $279 in 2025
The $279 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $16.81 · 2024: $337 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $383 · Education: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $383.48 |
| Education | $250.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $196.72 | 2024-2025 | Verzenio, Jaypirca |
| Seagen INC. | $99.00 | 2024 | |
| Exelixis INC. | $56.81 | 2024-2025 | Cabometyx |
| Sobi, INC | $45.62 | 2024-2025 | |
| Janssen Biotech, INC. | $41.33 | 2025 | Balversa, Erleada, Tecvayli |
| Pfizer INC. | $34.71 | 2024-2025 | |
| Kyowa Kirin, INC. | $32.69 | 2025 | |
| Novartis Pharmaceuticals Corporation | $28.31 | 2025 | |
| Incyte Corporation | $23.28 | 2025 | Jakafi |
| Merck Sharp & Dohme LLC | $22.94 | 2025 | Welireg, Keytruda |
| Array Biopharma INC | $20.08 | 2025 | Tukysa, Braftovi, Mektovi |
| Fresenius Kabi USA, LLC | $16.81 | 2023 | Idacio |
| Eisai INC. | $15.28 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Blackmon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.